PDE5A and erectile dysfunction: Further evidence might be taken from a recent study that compared two pharmacological strategies which are used to treat erectile dysfunction: compared to alprostadil, that is, prostaglandin E1, treatment with the inhibitor of phosphodiesterase 5A, sildenafil, was associated with a reduced risk of all-cause mortality and MI in men suffering from CAD35.